MX385405B - Composición inyectable en el vítreo de un ojo que comprende un inhibidor de cinasa y el uso de la misma para tratar una enfermedad ocular. - Google Patents

Composición inyectable en el vítreo de un ojo que comprende un inhibidor de cinasa y el uso de la misma para tratar una enfermedad ocular.

Info

Publication number
MX385405B
MX385405B MX2017014084A MX2017014084A MX385405B MX 385405 B MX385405 B MX 385405B MX 2017014084 A MX2017014084 A MX 2017014084A MX 2017014084 A MX2017014084 A MX 2017014084A MX 385405 B MX385405 B MX 385405B
Authority
MX
Mexico
Prior art keywords
eye
vitreous
treat
kinase inhibitor
injectable composition
Prior art date
Application number
MX2017014084A
Other languages
English (en)
Spanish (es)
Other versions
MX2017014084A (es
Inventor
Paul Ashton
Original Assignee
Eyepoint Pharmaceuticals Us Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eyepoint Pharmaceuticals Us Inc filed Critical Eyepoint Pharmaceuticals Us Inc
Publication of MX2017014084A publication Critical patent/MX2017014084A/es
Publication of MX385405B publication Critical patent/MX385405B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2017014084A 2015-05-05 2016-05-05 Composición inyectable en el vítreo de un ojo que comprende un inhibidor de cinasa y el uso de la misma para tratar una enfermedad ocular. MX385405B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562157257P 2015-05-05 2015-05-05
PCT/US2016/030912 WO2016179357A1 (en) 2015-05-05 2016-05-05 Injectable depot formulations

Publications (2)

Publication Number Publication Date
MX2017014084A MX2017014084A (es) 2018-06-20
MX385405B true MX385405B (es) 2025-03-18

Family

ID=57218334

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017014084A MX385405B (es) 2015-05-05 2016-05-05 Composición inyectable en el vítreo de un ojo que comprende un inhibidor de cinasa y el uso de la misma para tratar una enfermedad ocular.

Country Status (10)

Country Link
US (1) US20160324836A1 (enExample)
EP (1) EP3291812B1 (enExample)
JP (1) JP2018520093A (enExample)
CN (1) CN107530334A (enExample)
AU (1) AU2016258001B2 (enExample)
BR (1) BR112017023762A2 (enExample)
CA (1) CA2984637A1 (enExample)
MX (1) MX385405B (enExample)
RU (1) RU2017137763A (enExample)
WO (1) WO2016179357A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107278151A (zh) 2014-12-15 2017-10-20 约翰霍普金斯大学 舒尼替尼制剂及其在治疗青光眼中的使用方法
BR112018009644A2 (pt) 2015-11-12 2018-11-06 Graybug Vision Inc micropartículas agregantes sólidas modificadas na superfície, material injetável, processo para preparação de micropartículas agregantes sólidas modificadas na superfície, método para tratamento de um distúrbio ocular, e, uso de micropartículas agregantes sólidas modificadas na superfície
JP7217022B2 (ja) 2017-03-23 2023-02-02 グレイバグ ビジョン インコーポレイテッド 眼障害の治療のための薬物及び組成物
CA3057875A1 (en) 2017-05-10 2018-11-15 Graybug Vision, Inc. Extended release microparticles and suspensions thereof for medical therapy
CN114245737A (zh) * 2019-06-11 2022-03-25 司斐股份有限公司 微乳剂组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2156834A1 (en) * 2008-08-08 2010-02-24 S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. Ophthalmic pharmaceutical compositions comprising Sorafenib for the treatment of neoangiogenic pathologies of the eye
CN101890018B (zh) * 2009-05-22 2014-06-18 中国科学院化学研究所 一种酪氨酸蛋白激酶抑制剂及其制备方法
WO2013000909A1 (en) * 2011-06-28 2013-01-03 Bayer Intellectual Property Gmbh Topical ophthalmological pharmaceutical composition containing sorafenib
CN104204804B (zh) * 2011-11-11 2016-09-28 因特利凯有限责任公司 激酶抑制剂的组合及其用途
AR089248A1 (es) * 2011-12-14 2014-08-06 Abbvie Inc Composiciones que contienen inhibidores de quinasas

Also Published As

Publication number Publication date
AU2016258001B2 (en) 2020-06-04
WO2016179357A1 (en) 2016-11-10
EP3291812A4 (en) 2019-01-09
MX2017014084A (es) 2018-06-20
CA2984637A1 (en) 2016-11-10
US20160324836A1 (en) 2016-11-10
EP3291812B1 (en) 2021-09-01
CN107530334A (zh) 2018-01-02
BR112017023762A2 (pt) 2018-07-31
RU2017137763A (ru) 2019-06-05
EP3291812A1 (en) 2018-03-14
AU2016258001A1 (en) 2017-11-09
JP2018520093A (ja) 2018-07-26
RU2017137763A3 (enExample) 2019-08-21

Similar Documents

Publication Publication Date Title
CO2017004715A2 (es) Métodos y formulaciones para tratar enfermedades vasculares de los ojos
MX2019007586A (es) Composiciones que comprenden tacrolimus para el tratamiento de enfermedades inflamatorias intraoculares.
MX2017016655A (es) Formulaciones oftalmicas de inhibidores de tirosina quinasa, metodos de uso de las mismas y metodos de preparacion de las mismas.
MX2020001340A (es) Modelos celulares y terapias para enfermedades oculares.
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
MX2024007658A (es) Composiciones y metodos de uso de nintedanib para mejorar el exito de la cirugia del glaucoma.
EA201790398A1 (ru) Способы лечения заболевания печени
MX2021009673A (es) Moduladores de ror-gamma.
MX2017016517A (es) Composiciones estables al almacenamiento y metodos para el tratamiento de errores de refraccion del ojo.
HK1258588A1 (zh) 用於治療眼科疾病的化合物和製劑
NI201600115A (es) Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la hepatitis b.
MX2017002374A (es) Composiciones y metodos para tratar trastornos de la vision.
MX388380B (es) Composiciones para usarse en el incremento de los niveles de glóbulos rojos y el tratamiento de enfermedad de células falciformes.
CL2008001259A1 (es) Uso de una composicion que comprende un inhibidor del factor d del complemento para preparar un medicamento util para la inhibicion de la perdida de agudeza visual ociada con la degeneracion macular relacionada con la edad.
MX385405B (es) Composición inyectable en el vítreo de un ojo que comprende un inhibidor de cinasa y el uso de la misma para tratar una enfermedad ocular.
WO2016073771A3 (en) Pyrrolopyrimidine derivatives as mps1/ttk kinase inhibitors
MX2018012285A (es) Metodos de tratamiento para enfermedades colestasicas y fibroticas.
MX2016010215A (es) Composiciones y metodos de tratamiento y prevencion de degeneracion macular.
EA201692402A1 (ru) Лекарственные формы для местного применения и их использование
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
MX2017007000A (es) Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos para tratar o prevenir la fibrosis usando las mismas.
CL2019002839A1 (es) Métodos y composiciones para tratar enfermedades asociadas a la retina mediante inhibidores de ccr3.
MX2020012011A (es) Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.
BR112016016901A2 (pt) agentes para o uso no tratamento de inflamação retinal
UY36732A (es) Piridin pirazinonas novedosas como inhibidores de bromodominios de la familia bet